Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2026)

Cogent Biosciences' Cash from Financing Activities history spans 10 years, with the latest figure at $52.5 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 110.4% to $52.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $905.8 million through Mar 2026, up 3471.2% year-over-year, with the annual reading at $878.2 million for FY2025, 309.53% up from the prior year.
  • Cash from Financing Activities came in at $52.5 million for Q1 2026, down from $588.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $588.7 million in Q4 2025 to a low of -$256000.0 in Q2 2024.
  • The 5-year median for Cash from Financing Activities is $13.0 million (2023), against an average of $92.0 million.
  • Year-over-year, Cash from Financing Activities plummeted 100.16% in 2024 and then surged 2264011.54% in 2025.
  • Cogent Biosciences' Cash from Financing Activities stood at $315000.0 in 2022, then soared by 217.46% to $1.0 million in 2023, then tumbled by 97.4% to $26000.0 in 2024, then soared by 2264011.54% to $588.7 million in 2025, then plummeted by 91.08% to $52.5 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Cash from Financing Activities are $52.5 million (Q1 2026), $588.7 million (Q4 2025), and $217.4 million (Q3 2025).